Holen Sie sich die Stockscreener-App
320.26
0.74%
3.1666
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$317.09
Offen:
$318.42
24-Stunden-Volumen:
24,674
Relative Volume:
0.07
Marktkapitalisierung:
$6.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-16.65
EPS:
-19.24
Netto-Cashflow:
$-438.32M
1W Leistung:
+5.54%
1M Leistung:
+52.93%
6M Leistung:
+31.74%
1J Leistung:
+69.52%
1-Tages-Spanne:
$315.15
$320.78
1-Wochen-Bereich:
$272.72
$323.99
52-Wochen-Spanne:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| MDGL | 320.05 | 6.92B | 0 | -518.67M | -438.32M | -19.24 |
| VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Connor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH - Scrip
(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com
(MDGL) Trading Report - Stock Traders Daily
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India
3 High Growth Tech Stocks Leading The US Market - Simply Wall St
B. Riley Has Bullish Estimate for MDGL FY2024 Earnings - MarketBeat
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy - Yahoo Finance
Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance
FY2028 Earnings Forecast for MDGL Issued By Leerink Partnrs - MarketBeat
Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN
MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN
Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily
Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Expectations By $2.02 EPS - MarketBeat
MDGL stock soars to 52-week high, reaching $299.99 - Investing.com
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):